Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2023

Feb 25, 2023

29831_dirs_2023-02-24_c197199f-9ea5-49b1-bd41-ac68cf14ed97.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2023-02-22

Reporting Person: SUSMAN SALLY (Executive Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-02-22 Common Stock M 76043.0000 $30.1700 Acquired 195493.0000 Direct
2023-02-22 Common Stock F 13007.0000 $42.3800 Disposed 182486.0000 Direct
2023-02-22 Common Stock F 46291.0000 $43.7000 Disposed 136195.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-02-22 Stock Appreciation Rights $30.1700 M 76043.0000 Disposed 2023-02-22 Common Stock (76043.0000) Direct
2023-02-23 Stock Appreciation Rights $42.3000 A 43624.0000 Acquired 2028-02-23 Common Stock (43624.0000) Direct
2023-02-23 Stock Appreciation Rights $42.3000 A 37966.0000 Acquired 2030-02-23 Common Stock (37966.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 772.0000 Indirect

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F5: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F6: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.